Psychedelics California governor signs bill to promote state psychedelics research It aims to benefit veterans and citizens plagued by mental health complications Rowan Dunne3 days ago
Cannabis Overwhelming majority think rescheduling will occur under Trump: ATB survey The percentage was unexpectedly high at over 96% Rowan DunneOctober 8, 2025
Stock News Cannabis stocks and ETFs rally as Trump considers rescheduling That old chestnut Rowan DunneAugust 14, 2025
Psychedelics Psychedelic drug developer Cybin secures major financing deal The convertible debentures will raise up to half a billion Rowan DunneJuly 2, 2025
Cannabis Cannabis stocks slide after DEA decides to push back reclassification hearing Rescheduling of the plant in the U.S. is imminent, but we're not quite there yet Rowan DunneAugust 27, 2024
Cannabis Historic cannabis rescheduling imminent in the U.S., multiple sources say It will move from being a Schedule I substance to Schedule III Rowan DunneMay 1, 2024
Science and Research DEA sharply increases quantities of psychedelics, cannabinoids for 2024 research Substances being produced at a more rapid rate this year will include psilocybin, DMT and delta-9 THC Rowan DunneJanuary 4, 2024
Cannabis U.S. health department urges DEA to re-classify cannabis as a less dangerous substance Cannabis is currently scheduled under Schedule I which are deemed drugs with a high risk of abuse such as heroin Natalia Buendia CalvilloAugust 31, 2023
Legalization DEA proposes hiking Schedule I drug production for medical research After a spike in demand for research, the DEA is proposing increased quotas for controlled substances including MDMA, LSD, psilocybin and cannabis Natalia Buendia CalvilloOctober 18, 2021
Cannabis US DEA suggests big increase of cannabis and psilocybin production for research The agency says it supports research into the substances and it's necessary for the FDA to approve new quotas Kathryn TindaleSeptember 1, 2021